Related Experiment Video

Updated: Jul 19, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Reversing drug resistance in bcl-2-expressing tumor cells by depleting glutathione

D W Voehringer1, R E Meyn

  • 1Department of Genetics, Stanford University Medical School, Stanford, CA, USA.

Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|November 10, 2006
PubMed

Insights

This review explores how cancer cells resist chemotherapy by evading apoptosis, focusing on the bcl-2 protein family. It also discusses bcl-2

Area of Science:

  • Cancer Cell Physiology
  • Molecular Biology
  • Biochemistry

Background:

  • Cancer cells possess complex molecular pathways conferring resistance to therapeutic interventions.
  • Multidrug resistance is a significant challenge in cancer treatment, often involving resistance to apoptosis.

Purpose of the Study:

  • To review current understanding of tumor cell resistance mechanisms, specifically focusing on apoptosis evasion.
  • To discuss the role of the bcl-2 protein family in regulating apoptosis and antioxidant pathways.
  • To present potential strategies for overcoming therapeutic resistance with clinical utility.

Main Methods:

  • Review of existing scientific literature on cancer cell resistance pathways.
  • Analysis of the role of bcl-2 family proteins in apoptosis regulation.
  • Examination of the link between bcl-2, glutathione-mediated antioxidant pathways, and drug resistance.

Main Results:

  • The bcl-2 protein family plays a crucial role in regulating apoptosis in cancer cells.
  • Evidence suggests bcl-2 is involved in the regulation of glutathione-mediated antioxidant pathways.
  • Dysregulation of apoptosis and antioxidant pathways contributes to multidrug resistance in tumors.

Conclusions:

  • Understanding the bcl-2 family's role in apoptosis and antioxidant defense is key to overcoming cancer drug resistance.
  • Targeting these pathways may offer novel therapeutic strategies for enhancing treatment efficacy in cancer patients.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...